Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immucor -- Ignore unavailable to you. Want to Upgrade?

To: technetx who wrote (141)	8/11/1998 7:26:00 AM
From: Thomas Kirwin	Read Replies (1) \| Respond to of 422

CLMA Annual Conference & Exhibition Technetx, Immucor will be an exhibitor at the 1998 CLMA Annual Conference & Exhibition scheduled to be held in my own back yard, Philadelphia, Pennsylvania on August 19-23. clma.org The list of participants is very impressive. Hmmmmmmm, just maybe I'll attend. Abbott Diagnostics Booth 1751, 1657 Biopool International Booth 1827 Gamma Biologicals, Inc. Booth 2139 Immucor, Inc. Booth 1151 Johnson & Johnson Diagnostic Company Booth 1527 Up and Coming.... i-STAT Corporation Booth 327 Regards, Tom

To: technetx who wrote (141)	8/15/1998 2:51:00 PM
From: Thomas Kirwin	Read Replies (1) \| Respond to of 422

Josef Wilms Info - Immucor 10-K (08/27/97) Technetx, I don't have any reliable data on instrument sales at this time. Mr. Gallup may make an announcement by September 5th as he indicated that placements would be made within the next 60 days from the July 5th ABS2000 FDA Approval press release date. As for the Josef Wilms matter the only info available is contained in the following excerpt from Immucor's 10-K filed with the SEC on 08/27/97. 5. ACCOUNTS RECEIVABLE, OTHER In fiscal 1997, Mr. Josef Wilms, the former president of the Company's German subsidiary, Immucor GmbH, borrowed, prior to his resignation, $300,000 from the Company at 6% interest, secured by his warrants to purchase 143,750 shares of the Company's Common Stock. At May 31, 1997, the amount outstanding under this loan was $309,000 including accrued interest. In July 1997, management of the Company discovered that Mr. Wilms had caused Immucor GmbH to make unauthorized loans to him since 1994. The amounts advanced were documented in the records of Immucor GmbH, including interest rates ranging from 7.75% to 9.5%, and were generally paid down by the end of each accounting period, but were not disclosed to the Company's management. The largest aggregate amounts outstanding under the Immucor GmbH loans were $29,560 in fiscal 1994, $290,422 in fiscal 1995, $669,398 in fiscal 1996 and $1,310,730 in fiscal 1997. At May 31, 1997, the aggregate outstanding amount under the Immucor GmbH loan was approximately $1,300,000. Mr. Wilms, his wife and son have granted liens on certain property owned by them in Germany and Portugal to collateralize the loans from the Company and Immucor GmbH, and Mr. Wilms has agreed to grant liens on additional property owned by him and located in the United States. Management believes that the value of the collateral significantly exceeds the outstanding loan amounts. Mr. Wilms has agreed to pay all amounts borrowed from the Company and Immucor GmbH, plus interest at 8.25%, plus the Company's expenses in securing the loans, by October 31, 1997. If these amounts are not fully repaid by that date, the Company intends to arrange for the sale of some or all of the collateral to the extent necessary to recover the unpaid balance. Mr. Wilms is expected to remain as a consultant to the Company through December 31, 1997 on European sales and marketing matters. sec.gov Perhaps there will be an update contained in the next 10-K unless the loan has been paid in full as agreed. Regards, Tom

To: technetx who wrote (141)	8/17/1998 8:11:00 AM
From: Thomas Kirwin	Read Replies (1) \| Respond to of 422

ABS2000 Sales Possibility - University HealthSystem Consortium Technetx, An old Immucor news item contained in The Week in Business section of Atlanta Business Chronicle dated July 15, 1996 reported..... "Immucor has signed a three-year contract to supply its current products and the ABS2000 after approval to the University HealthSystem Consortium, a buying group of 66 academic medical centers and 55 affiliated hospitals. Immucor considers the deal an endorsement of its blood bank instrument under review by the FDA, Still said. The company also has won a three-year contract from one of the largest U.S.-based private laboratory chains." amcity.com Wow, if Immucor closes a deal with the University HealthSystem Consortium to place one ABS2000 unit at each site the total number of placements could be as high as 121. The revenue generated from this deal alone could be in excess of $9 million with an annual reagent trail of $3.6 million. Lets go Immucor! Regards, Tom